ClinicalTrials.Veeva

Menu
U

University of California, San Diego | UCSD Moores Cancer Center

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Pembrolizumab
Gemcitabine
Nivolumab
Ibrutinib
Palbociclib
Cetuximab
Paclitaxel
BMS-936558
Lenalidomide
Obinutuzumab

Parent organization

This site is a part of University of California, San Diego

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

23 of 95 total trials

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma a...

Enrolling
Lymphoma, Non-Hodgkin
Drug: Obinutuzumab
Drug: CC-99282

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and activity of divarasib combined with other anti-cancer therapies in pa...

Enrolling
Non-Small Cell Lung Cancer
Drug: Pembrolizumab
Drug: Carboplatin

We hypothesize that GA101 - Obinutuzumab in combination with HDMP is well tolerated and will induce similar if not higher response rates than the one...

Active, not recruiting
CLL
Drug: GA101/HDMP

This randomized, double-blind, placebo-controlled, two-arm study will assess the safety and efficacy of pertuzumab in addition to chemotherapy plus t...

Active, not recruiting
Breast Cancer
Drug: 5-Fluorouracil
Drug: Cyclophosphamide

This is a Phase 2, multicenter, two-stage, open-label, parallel-group study designed to evaluate the efficacy and safety of vudalimab (XmAb20717) in...

Enrolling
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Endometrial Cancer
Biological: vudalimab

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NR...

Enrolling
Melanoma
Solid Tumor, Adult
Drug: KIN-2787 and binimetinib
Drug: KIN-2787

The goal of this study is to test A2B694, an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cance...

Enrolling
Ovarian Neoplasms
NSCLC, Recurrent
Diagnostic Test: xT CDx with HLA-LOH Assay
Biological: A2B694

This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036...

Enrolling
Advanced Solid Tumors
Colorectal Cancer
Drug: Inavolisib
Drug: Atezolizumab

The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants...

Enrolling
Relapsed Adult AML
Leukemia, Myeloid, Acute
Drug: Venetoclax Oral Tablet
Drug: Tuspetinib

The purpose of this study is to determine the overall response rate of patients with Multiple Myeloma to the combination of Daratumumab, Ixazomib, Po...

Active, not recruiting
Relapsed/Refractory Multiple Myeloma
Drug: Ixazomib
Drug: Dexamethasone

The purpose of this study is to determine whether pembrolizumab, when given after salvage surgery, is effective in increasing the time a person with...

Active, not recruiting
Squamous Cell Carcinoma of the Head and Neck
Drug: Pembrolizumab

Multicenter, open-label, prospective treatment protocol that provides continued access to ibrutinib to subjects who have completed parent ibrutinib s...

Invitation-only
Solid Tumor
Graft Vs Host Disease
Drug: Ibrutinib

The purpose of the study is to determine whether ibrutinib in combination with GA101 - Obinutuzumab might be useful for the treatment of CLL. This st...

Active, not recruiting
Chronic Lymphocytic Leukemia
Drug: ibrutinib
Drug: GA101

Lung cancer is the leading cause of cancer deaths. Advances in the systemic treatment of non-small cell lung cancer (NSCLC) have increased survival i...

Active, not recruiting
Lung Cancer
Drug: Abemaciclib
Drug: Osimertinib

This is a prospective, two arm, international, multicenter, randomized, open-label Phase III study evaluating the addition of 2 years of palbociclib...

Active, not recruiting
Breast Cancer
Drug: Standard Adjuvant Endocrine Therapy
Drug: Palbociclib

This is a randomized, double-blind, study that compares pembrolizumab (MK-3475) with placebo given as adjuvant therapy in participants with high-risk...

Active, not recruiting
Carcinoma, Squamous Cell
Drug: Placebo
Biological: Pembrolizumab 400 mg

This is a prospective, multi-center, open-label, non-randomized, multi-arm phase II trial to evaluate the efficacy of combination therapy with pembro...

Active, not recruiting
Hypopharynx Cancer
Nasopharynx Cancer
Drug: Pembrolizumab, Cetuximab

This is a single-arm, multi-site, open-label trial of pembrolizumab (MK-3475) used in combination with standard, cisplatin-based, definitive chemorad...

Active, not recruiting
Laryngeal Cancer
Squamous Cell Carcinoma
Radiation: Radiation
Drug: pembrolizumab (MK-3475)

This is an open-label, non-randomized, Phase I, dose escalation/dose expansion study in cohorts of patients with relapsed, resistant, or metastatic H...

Enrolling
HPV Associated Cancers
Drug: Pembrolizumab
Drug: TGN-S11

This 2-part study will evaluate the safety and efficacy of pembrolizumab (MK-3475) compared to placebo in participants with surgically resected high-...

Active, not recruiting
Melanoma
Other: Placebo
Biological: Pembrolizumab

Trial sponsors

University of California San Diego logo
Bristol-Myers Squibb (BMS) logo
Celgene logo
Roche logo
Pfizer logo
A
Genentech logo
Merck Sharp & Dohme (MSD) logo
D
M

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems